Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | ALK F1245C |
Therapy | hALK.CAR T cells + Lorlatinib |
Indication/Tumor Type | neuroblastoma |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ALK F1245C | neuroblastoma | sensitive | hALK.CAR T cells + Lorlatinib | Preclinical - Pdx & cell culture | Actionable | In a preclinical study, Lorbrena (lorlatinib) treatment resulted in increased death of cells derived from a patient-derived xenograft model of neuroblastoma harboring ALK F1245C when co-cultured with hALK.CAR T cells compared to control CAR-T cells in culture and the combination inhibited tumor growth and increased survival in a patient-derived xenograft (PDX) model (PMID: 38039964). | 38039964 |
PubMed Id | Reference Title | Details |
---|---|---|
(38039964) | ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK.CAR-T cells. | Full reference... |